Vertex Pharmaceuticals
VRTX
475 hedge funds and large institutions have $27.3B invested in Vertex Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 173 increasing their positions, 162 reducing their positions, and 25 closing their positions.
204% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 25
10% more funds holding
Funds holding: 431 → 475 (+44)
7% more repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 162
4% more capital invested
Capital invested by funds: $26.2B → $27.3B (+$1.05B)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
41% less call options, than puts
Call options by funds: $282M | Put options by funds: $481M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$205M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$109M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$86.1M |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$71.6M |
| 5 |
HCM
Hoplite Capital Management
New York
|
+$68.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$422M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$300M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$195M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$141M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$118M |
VRTX Hedge Fund Activity: Q4 2014 in Review
475 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2014, worth a combined $27.3B — up 4% from $26.2B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new VRTX positions and 25 closed out — a net gain of 51 holders — while 173 added to existing stakes and 162 trimmed.
The largest buyer was Winslow Capital Management, opening a new position worth an estimated $205M. The largest seller was Jennison Associates, cutting an estimated $422M.
- 475 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2014, up from 431 in Q3 2014.
- Funds reported $27.3B of Vertex Pharmaceuticals stock for Q4 2014, up 4% quarter-over-quarter.
- 76 funds opened new Vertex Pharmaceuticals positions in Q4 2014 and 25 closed out, a net change of +51 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2014 was Winslow Capital Management, an estimated $205M added.
- The largest Vertex Pharmaceuticals seller in Q4 2014 was Jennison Associates, an estimated $422M sold.
Based on aggregated 13F filings for Q4 2014.